Challenges of advanced hepatocellular carcinoma

doi:10.3748/wjg.v22.i34.7645

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 22, Issue 34

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (10519)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-5) series.

Item

Count

PDF

875

WORD

251

HTML

6511

Tables (1-5)

138

Sum=7775

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

377

Download

362

Sum=739

Publishing Process of This Article

Item

Count

Browse

892

Download

1113

Sum=2005

Sep 14, 2016 (publication date) through Apr 23, 2024

Times Cited of This Article

Times Cited (114)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Sep 14, 2016; 22(34): 7645-7659
Published online Sep 14, 2016. doi: 10.3748/wjg.v22.i34.7645

Table 4 Principal ongoing studies in advanced hepatocellular carcinoma with new molecular targeted therapies

Study	Drug	Status
A multicenter, open-label, phase 3 trial to compare the efficacy and safety of lenvatinib (e7080) vs sorafenib in first-line treatment of subjects with unresectable hepatocellular carcinoma	Lenvatinib vs sorafenib	Active, not recruiting
Study of regorafenib after sorafenib in patients with hepatocellular carcinoma (RESORCE)	Regorafenib vs placebo	Recruiting
A study of dovitinib vs sorafenib in adult patients with hepatocellular carcinoma as a first line treatment	Dovitinib vs sorafenib	Completed (phase 2)
A study of nivolumab vs sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma	Nivolumab vs sorafenib	Recruiting

Citation: Colagrande S, Inghilesi AL, Aburas S, Taliani GG, Nardi C, Marra F. Challenges of advanced hepatocellular carcinoma. World J Gastroenterol 2016; 22(34): 7645-7659
URL: https://www.wjgnet.com/1007-9327/full/v22/i34/7645.htm
DOI: https://dx.doi.org/10.3748/wjg.v22.i34.7645